Point-of-Care Drug Reconstitution Systems to 2020
|発行||Greystone Research Associates||商品コード||228359|
|ポイントオブケア薬剤再構成：治療市場、技術、戦略、見通し Point-of-Care Drug Reconstitution Systems to 2020|
|出版日: 2014年01月13日||ページ情報: 英文||
Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biological NCEs. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent. The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. This report examines commercial drug reconstitution devices and systems and their impact on the injectable drug delivery sector.